Cardarella相关文献与解析，生知库 | 链接生命科学的每一步

Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival

未经治疗的晚期非小细胞肺癌患者的间质性肺异常与较短的生存期相关。

doi:10.1016/j.ejrad.2015.01.021

Nishino, Mizuki; Cardarella, Stephanie; Dahlberg, Suzanne E; Araki, Tetsuro; Lydon, Christine; Jackman, David M; Rabin, Michael S; Hatabu, Hiroto; Johnson, Bruce E

Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI

在接受 EGFR-TKI 治疗的 EGFR 突变型晚期非小细胞肺癌患者中，8 周时肿瘤体积缩小与更长的生存期相关。

期刊:Journal of Thoracic Oncology

影响因子:20.8

doi:10.1097/JTO.0b013e318294c909

Nishino, Mizuki; Dahlberg, Suzanne E; Cardarella, Stephanie; Jackman, David M; Rabin, Michael S; Hatabu, Hiroto; Jänne, Pasi A; Johnson, Bruce E

The impact of genomic changes on treatment of lung cancer

基因组变化对肺癌治疗的影响

期刊:American Journal of Respiratory and Critical Care Medicine

影响因子:19.4

doi:10.1164/rccm.201305-0843PP

Cardarella, Stephanie; Johnson, Bruce E

RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0

RECIST 1.1 在接受 EGFR 酪氨酸激酶抑制剂治疗的 EGFR 突变 NSCLC 患者中的应用：与 RECIST 1.0 的比较

期刊:American Journal of Roentgenology

影响因子:6.1

doi:10.2214/AJR.12.9668

Nishino, Mizuki; Cardarella, Stephanie; Jackman, David M; Ramaiya, Nikhil H; Rabin, Michael S; Hatabu, Hiroto; Jänne, Pasi A; Johnson, Bruce E

The introduction of systematic genomic testing for patients with non-small-cell lung cancer

对非小细胞肺癌患者引入系统性基因组检测

期刊:Journal of Thoracic Oncology

影响因子:20.8

doi:10.1097/JTO.0b013e3182745bcb

Cardarella, Stephanie; Ortiz, Taylor M; Joshi, Victoria A; Butaney, Mohit; Jackman, David M; Kwiatkowski, David J; Yeap, Beow Y; Jänne, Pasi A; Lindeman, Neal I; Johnson, Bruce E

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs

EGFR突变转移性肺腺癌患者接受EGFR-TKI治疗后的五年生存率

Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer

非小细胞肺癌多重预测性生物标志物筛查的成本效益

Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival

未经治疗的晚期非小细胞肺癌患者的间质性肺异常与较短的生存期相关。

Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI

在接受 EGFR-TKI 治疗的 EGFR 突变型晚期非小细胞肺癌患者中，8 周时肿瘤体积缩小与更长的生存期相关。

The impact of genomic changes on treatment of lung cancer

基因组变化对肺癌治疗的影响

RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0

RECIST 1.1 在接受 EGFR 酪氨酸激酶抑制剂治疗的 EGFR 突变 NSCLC 患者中的应用：与 RECIST 1.0 的比较

The introduction of systematic genomic testing for patients with non-small-cell lung cancer

对非小细胞肺癌患者引入系统性基因组检测